Can a Nasal Spray Stop the Flu Before It Starts? Leyden Labs Thinks So

Like clockwork, every year brings with it a wave of sniffles, fevers, and, for many, serious health risks otherwise known as flu season. While vaccines remain our primary defense, they aren’t always perfect. Now, a biotech company based in the Netherlands is developing a new tool that could change how we protect ourselves: a nasal spray designed to block viruses at the entry point.

Leyden Labs, located in the Leiden Bio Science Park, is developing an innovative nasal spray that aims to prevent influenza viruses from entering the body. Unlike traditional treatments that fight the virus after infection, this approach focuses on fortification at the source.

A Physical Barrier in the Nose

While vaccines work by training your immune system to fight a virus after it has already entered your system, Leyden Labs’ PanFlu spray takes a different route. It forms a physical barrier of antibodies inside the nose.

This antibody-based shield prevents the virus from entering the mucous membranes. Because it relies on these antibodies to block entry rather than stimulating the body’s own immune response, it doesn’t significantly activate the immune system.

One of the most promising aspects of this technology is its “broadly acting” nature. The spray uses antibodies that can protect against multiple flu viruses simultaneously. This means the product wouldn’t require the constant yearly redevelopment that current flu shots do. A single daily dose is expected to provide broad protection, potentially guarding against new variants and even pandemic strains such as avian flu.

Protecting the Most Vulnerable

Globally, influenza causes approximately 1 million deaths and 5 million hospitalizations each year. Leyden Labs is initially focusing its efforts on high-risk groups—people for whom a flu infection could lead to hospitalization or worse. Currently, the spray is in clinical development with researchers rigorously testing its safety and effectiveness in humans.

A Complement to Vaccines, Not a Replacement

The nasal spray isn’t intended to replace your annual flu shot. Experts emphasize that vaccines remain crucial for long-lasting protection that can persist for weeks, even years. However, flu vaccines typically have an effectiveness of about 30–40 percent and rely on the body’s immune response kicking in after exposure.

Read Also: Antibiotic-Resistant Infections in the Netherlands: What You Need to Know

Leyden Labs’ product acts as an additional layer of defense—a “mask in a bottle,” so to speak. By combining the long-term systemic protection of vaccines with the immediate, localized barrier provided by the nasal spray, we could see a drastic reduction in severe flu cases.

Looking ahead, the company isn’t stopping at the flu. They are applying this same antibody-based technology to develop a similar nasal product targeting coronaviruses, including future variants. As clinical trials progress, this simple daily spray could soon become a vital new weapon in our global fight against respiratory viruses.